Following reports on the skyrocketing cost of the EpiPen emergency allergy treatment, drugmaker Mylan has been heavily criticized for putting profit over patients. Even the recent expansion of its savings card program has been slammed as being more beneficial to Mylan than it is for consumers. Now, the nation’s largest group of pediatricians are calling on the company to rethink its pricing of the drug. [More]
